Notícias

RapAdmin

VO2PeakBrainHealth-2
VO2PeakBrainHealth-22752×1536 485 KB

A cross-sectional study from UT Southwestern Medical Center and the University of Texas at Dallas looked at whether cardiorespiratory fitness is linked to brain structure across the adult lifespan. Fitness was measured directly as peak oxygen uptake (VO2peak) on a treadmill. The researchers scanned 172 sedentary but healthy adults aged 22 to 81 with 3-Tesla MRI and tested fluid cognition in 147 of them. Age was strongly associated with thinner cortex and lower gray matter volume throughout the brain. Fitness showed no association with total gray matter or average cortical thickness. One region stood out. In the right superior parietal lobe, volume fell with age among the less fit participants but stayed flat among those above the median fitness of 25 mL/kg/min. Larger volume in this region was modestly associated with better fluid cognition. The findings hint that fitness benefits the brain in specific regions, but they cannot establish cause and effect.

Your brain shrinks as you age. That much is well established, and this study confirms it in detail. Across 172 healthy adults aged 22 to 81, each extra decade of age came with roughly 3 percent less total gray matter and a measurably thinner cortex. The open question is whether anything you control changes that trajectory, and aerobic fitness has long been a leading candidate.

The researchers tested this with unusually rigorous measurements. Instead of relying on questionnaires or step tests, they put every participant on a treadmill and measured peak oxygen uptake directly, collecting expired air until exhaustion. Each person also had a high-resolution brain scan and a cognitive battery covering reasoning, long-term memory, working memory, processing speed and executive function.

The main result is less tidy than most exercise headlines. Once age, sex, education and head size were accounted for, fitness did not predict total gray matter volume or average cortical thickness. A trend toward thicker cortex in fitter people narrowly missed statistical significance. Across most of the cortex, age dominated and fitness seemed not to matter.

One region broke the pattern. The right superior parietal lobe sits near the top and back of the head and supports spatial attention, reasoning and working memory. Here the link between age and volume depended on fitness. Among participants below the median VO2peak of 25 mL/kg/min, volume fell by about 39 cubic millimeters per year, roughly 12 percent between ages 30 and 70. Among those above the median there was no detectable decline. People with more volume in this region also scored somewhat better on fluid cognition, even after accounting for age and fitness.

It makes sense that fitness would matter here. The parietal cortex is among the regions that thin early in mild cognitive impairment and Alzheimer’s disease, and earlier studies have linked fitness to parietal structure and blood flow. The region also sits in a vascular border zone where blood flow drops with age, so better cardiovascular function could plausibly protect it.

This is a single snapshot in time, so it cannot show that fitness slows brain aging within any one person. Fitter older adults may differ from less fit peers in body weight, blood pressure and medication use, and none of these were adjusted for. The sample was mostly white, highly educated and deliberately sedentary, which limits both who the results apply to and the range of fitness studied. The effect appeared in only one region of the cortex, and only for volume, not thickness.

What the study adds is gold-standard fitness measurement applied across the whole adult lifespan rather than only in older adults, plus a specific anatomical target for future trials. The real test will be randomized studies that raise VO2peak and track the right superior parietal lobe over years. Until then, the result is a promising signal rather than proof.

Actionable Insights

  • The fitness line that mattered was a VO2peak of about 25 mL/kg/min, roughly 7 METs. Above it, right superior parietal volume showed no age-related decline. Below it, volume fell about 0.3 percent per year, around 12 percent from age 30 to 70. At age 70, the fitter group’s predicted volume was about 14 percent larger. [Confidence: Low to Medium]
  • At the whole-brain level, the fitness effect was small and statistically uncertain. Each extra 10 mL/kg/min of VO2peak corresponded to total gray matter about 2 years “younger”. The data are consistent with anything from 4 years older to 8 years younger. Average cortical thickness looked somewhat better, about 5 years “younger” per 10 mL/kg/min, but this narrowly missed significance. [Confidence: Low]
  • The link between parietal volume and cognition is modest. After adjustment, parietal volume explained roughly 4 percent of the person-to-person variation in fluid cognition. [Confidence: Medium]
  • The practical move is to know your VO2peak, either measured or estimated, and train to raise it. Structured aerobic programs in sedentary adults commonly raise VO2peak by 10 to 20 percent. In meta-analysis, each 1-MET gain in fitness is associated with about 13 percent lower all-cause mortality. Treat the brain-structure benefit as a plausible bonus on top of well-proven cardiometabolic benefits, not a proven effect in its own right. [Confidence: Medium]

Context and Source

  • Open Access Paper: Associations of cardiorespiratory fitness with cerebral cortical thickness and gray matter volume across the adult lifespan, 2025.
  • Institutions: University of Texas Southwestern Medical Center (Department of Neurology); Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas; Center for Vital Longevity, University of Texas at Dallas; National Institute of Advanced Industrial Science and Technology, Japan (co-affiliation)
  • Country: United States
  • Journal: Journal of Applied Physiology (American Physiological Society), 2025.
  • Impact evaluation: The impact score of this journal is approximately 3.0 (Clarivate JIF; Scopus CiteScore approximately 5.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

BrownFat-2
BrownFat-22752×1536 490 KB

Brown fat burns calories to generate heat, but this ability fades as we get older. This study maps out exactly why this happens: as fat ages, local immune cells begin releasing an inflammatory molecule (IL-1β) that essentially short-circuits the neighboring fat cells. This inflammation causes the fat cells to produce their own local stress hormones, which hit an internal “off switch” (the glucocorticoid receptor) and lock the brown fat in a dormant, low-energy state. In young, healthy bodies, cold exposure triggers nerve signals that clear out this inflammation, allowing the fat to turn back on and generate heat. However, chronic inflammation in aged fat blocks this natural response, leading to cold intolerance and a sluggish metabolism. Most importantly, researchers found that giving aged subjects a drug (RU 486) to block these local stress receptors successfully reactivated their brown fat, boosted their overall calorie burn, and restored their ability to adapt to the cold.

Brown fat acts as a metabolic engine, utilizing blood sugar and lipids to generate heat rather than storing them. The gradual loss of this calorie-burning capacity during aging strongly correlates with metabolic decline and frailty. Recent analyses reveal that brown fat cells are not identical. They exist in two distinct states: a highly active, heat-producing state driven by the uncoupling protein UCP1, and a dormant, low-energy state. The transition between these states is tightly controlled by a localized interaction between the nervous system and the immune system.

The core regulatory mechanism identified in this research revolves around tissue-level inflammation. Immune cells residing within the fat tissue secrete an inflammatory molecule called IL-1β. This molecule acts on nearby brown fat cells to stabilize a specific enzyme known as H6PD, preventing its normal cellular disposal. H6PD acts as a catalyst for the local production of active stress hormones, or glucocorticoids, directly inside the fat tissue. These localized stress hormones activate the cell’s glucocorticoid receptor. This receptor activation subsequently shuts down UCP1 production, turning off the metabolic machinery required to burn calories and locking the cell in the dormant state.

When a young organism is exposed to cold temperatures, sympathetic nerves release neurotransmitters that directly instruct the immune cells to stop secreting IL-1β. Without this inflammatory signal, H6PD degrades, local stress hormone production plummets, and the fat cells transition into the highly active state to generate heat.

Aging severely disrupts this biological system. Older subjects exhibit a massive accumulation of IL-1β-secreting immune cells within their brown fat. This chronic, localized inflammation creates a continuous production of active stress hormones, even during severe cold exposure. Consequently, aged brown fat remains trapped in the dormant state, rendering the organism cold-intolerant and metabolically suppressed.

The defining breakthrough of this study is the pharmacological reversal of this age-related metabolic decline. By administering mifepristone (RU-486), a drug that blocks the glucocorticoid receptor, researchers successfully bypassed the immune-driven blockade. Antagonizing these stress receptors in aged subjects permitted the dormant fat cells to transition back to the highly active state. This intervention significantly raised whole-body energy expenditure and restored cold survival rates to near-youthful levels. This research isolates a precise pathway where localized inflammation drives metabolic aging, offering a targetable mechanism to restore calorie-burning capacity and systemic energy expenditure.

Actionable Insights

Systemic or tissue-specific interventions targeting glucocorticoid signaling present immediate translational potential for longevity and metabolic health. The data indicate that chronic localized inflammation (specifically IL-1β) directly suppresses metabolic rate by mimicking local stress signaling in fat tissue. Limiting systemic inflammation may preserve thermogenic capacity by maintaining the sensitivity of brown fat to noradrenaline.

The pharmacological blockade of the glucocorticoid receptor using RU-486 yielded substantial, quantifiable benefits in older subjects. In aged models exposed to cold for one day, RU-486 increased the population of high-thermogenic BA-H cells from a median of 10.6% to 32.8%. This represents an absolute increase of 22.2% and a relative increase of 3.09-fold (estimated Cohen’s d > 1.5, indicating a massive effect size). Functionally, this cellular shift rescued survival. Aged control subjects faced a 25% absolute risk of mortality within two days of severe cold exposure, whereas RU-486 stabilized body temperatures and mitigated weight loss, restoring functional thermogenesis. While chronic systemic RU-486 administration carries clinical side effects, this study was only 7 days long and demonstrated significant modifications and functional improvements. These findings suggest that a pulsed dosing strategy may provide signficant benefit, and also strongly supports the development of tissue-targeted glucocorticoid inhibitors or IL-1β suppressing protocols to safely elevate baseline energy expenditure and metabolic resilience in older adults.

Context/Source

  • Open Access Paper: Bistable regulation of adipocyte heterogeneity governs thermogenesis, Nov. 11, 2026.
  • Institutions: Beckman Research Institute at City of Hope Medical Center (USA), California Institute of Technology (USA), Wuhan University (China), Marche Polytechnic University (Italy)
  • Country: USA, China, Italy
  • Journal: Nature
  • Impact Evaluation: The impact score of this journal is 64.8, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Elite impact journal.

Leitura Relacionada:

RapAdmin

SingaporeLongevitySurvey16_9-2
SingaporeLongevitySurvey16_9-22752×1536 482 KB

Researchers at Singapore Management University and the National University of Singapore ran a preregistered, door-to-door national survey of 2,003 Singapore adults to find out who would take a repurposed chronic-disease drug, framed as a health optimization medication, and why. The answers were sobering for the field. Even told to assume perfect physical and mental health forever, 71 percent wanted to live no more than ninety years and only 8 percent wanted to pass 120. On willingness to take such a medication, 36 percent agreed, 30 percent disagreed, and 32 percent, sat neutral. Structural equation modeling found that one variable dominated everything else: whether people believed the drug would work. Perceived efficacy predicted willingness roughly four times more strongly than perceived risk and ten times more strongly than ethical concerns.

Geroscience has spent two decades building a case that aging is modifiable. Comparatively little attention has gone to the question of whether anybody would actually take the resulting drugs. The assumption running quietly beneath the field is that demand is latent and enormous, waiting only for a compound to clear regulatory approval. This survey tests that assumption in a country that is aging faster than almost anywhere else, and the assumption does not completely hold up.

Most published work on public attitudes toward longevity drugs rests on small convenience samples, often a few hundred mostly female Western respondents recruited online. This study sent trained interviewers to 9,781 addresses across Singapore, sampled postal codes in proportion to population and stratified by housing type and region, and selected within households by whoever had the next birthday. It was preregistered before data collection. The questionnaire ran in all four official languages. That is a substantially more defensible foundation than the field has had.

The first finding is about how long people want to live, and it is clear that people in Singapore have quite modest goals. Respondents were asked to imagine they could maintain optimal physical and mental health forever. Under that framing, which removes every ordinary objection about decline and dependency, 65 percent still chose sixty to ninety years. Another 6 percent wanted sixty or less. Only 2 percent chose 120 to 150 years. An American study using similar framing found nearly 80 percent wanting to live past 120. The gap is enormous and the authors attribute it to culture rather than to health perception, which is consistent with prior work showing Eastern populations desire shorter lives than Western ones.

desired_lifespan_singapore2
desired_lifespan_singapore23388×2068 329 KB

The second finding concerns the drugs themselves. Opinion split almost evenly three ways. Thirty-six percent said they would want to take a health optimization medication, 30 percent said they would not, and 32 percent declined to take a side.

The third finding is the one that matters for anyone trying to move those numbers. When the researchers modeled willingness against seven theoretically motivated predictors, one of them swamped the rest. Belief that the medication would improve one’s health carried a standardized coefficient of 0.53. The next largest, perceived health risk, came in at negative 0.14. Ethical concerns managed negative 0.05. Worry about chronic disease, 0.06. Whether a person had ambitious life goals, or wanted a long life at all, predicted essentially nothing once efficacy belief was accounted for.

The practical reading is clear. Arguments about whether life extension is natural, fair, or socially sustainable move almost nobody. Evidence that a drug works moves nearly everybody who can be moved.

The authors write that although several relationships reached significance, their practical relevance appears limited, and that the theory they set out to test may not be the right framework. One oddity went in the wrong direction entirely: people who worried more about an overpopulated elderly society were more willing, not less.

Insights

The headline number is that perceived efficacy carried a standardized coefficient of 0.53 toward willingness, in a model explaining 39 percent of the variance. Translated into the actual measurement scale, a one standard deviation rise in belief that a medication would improve your health corresponds to roughly 0.61 points of movement on a five-point willingness scale. By comparison, a one standard deviation rise in perceived health risk moves willingness down only 0.16 points, and ethical concern moves it down 0.06. Efficacy belief is therefore roughly four times more influential than safety concern and about ten times more influential than ethical objection. Squaring the coefficients suggests efficacy belief alone accounts for roughly three quarters of everything the model explains.

Second, don’t assume that people who want to live a long time are the only people in the longevity market. Desired lifespan had no relationship to willingness at all, with a coefficient of negative 0.009 and a p-value of 0.59. The mediation hypothesis connecting life goals to drug willingness through desired lifespan failed outright. Someone’s stated enthusiasm for longevity tells you nothing useful about whether they would take a pill.

Third, note the modal response was neutral at 32 percent. The persuadable middle is larger than either committed camp.

Fourth, 71 percent of respondents wanted ninety years or fewer even with perfect health guaranteed. Messaging built around radical life extension targets roughly 8 percent of this population, surprising as it may be be for people in the longevity enthusiasts group.

Context and Source

  • Open Access Paper: Life aspirations, risk-benefit perceptions, and public acceptance of candidate gerotherapeutic medications: a preregistered national survey in Singapore
  • Institutions: College of Integrative Studies, Singapore Management University; Healthy Longevity Translational Research Programme and NUS Academy for Healthy Longevity, Yong Loo Lin School of Medicine, National University of Singapore; Department of Human Movement Sciences, Vrije Universiteit Amsterdam; EvidencePointSA, Singapore.
    Country: Singapore, with Netherlands collaboration.
  • Journal: Frontiers in Aging (Frontiers Media)
  • Impact evaluation: The impact score of this journal is 4.9, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

RapAdmin

MuscleCellGraftForAging-2
MuscleCellGraftForAging-22752×1536 499 KB

Researchers at the Chinese Academy of Sciences took muscle stem cells from a mouse’s own thigh, grew and differentiated them in culture, then injected the resulting myocytes under the skin of the animal’s back. The cells organized into vascularized, mature muscle tissue that contracted spontaneously and survived at least three months. In 18-month-old female mice, these grafts were associated with higher lean mass, roughly 40 percent greater running distance, 16 percent higher grip strength, modestly higher bone density, lower white cell and liver enzyme levels, reduced hepatic senescence staining, better Y-maze performance, and nearly doubled circulating FGF21. Similar metabolic benefits appeared in diet-induced obese mice. The team also engineered grafts to secrete parathyroid hormone or growth hormone, correcting experimental hypoparathyroidism.

Exercise is the closest thing geroscience has to a universal intervention. It improves muscle, bone, metabolism, mood and cognition at once, and it does so partly because contracting muscle is an endocrine organ, releasing a stream of signaling proteins called myokines into the bloodstream. The field has spent two decades trying to bottle this. Most attempts pick one myokine, irisin or BDNF or FGF21, and try to deliver it as a drug. The results have been underwhelming, which suggests that the benefit may lie in the whole secretome rather than any single component.

This paper takes a different route. Instead of delivering a molecule, it delivers the organ.

The procedure is conceptually simple. Take a small biopsy from the animal’s own quadriceps, isolate the muscle stem cells, expand them in culture, push them one step down the differentiation path into myocytes, then inject them under the skin of the back in a gel scaffold. What happens next is the surprising part. The cells do not die, which is what usually happens to transplanted myoblasts. They organize into recognizable muscle tissue with multiple fiber types, recruit a blood supply from the host, and begin contracting. Not in response to a nerve signal, because there is no nerve. They contract on their own, visibly, continuously, for months.

A small patch of muscle twitching under the skin would be a curiosity if nothing else followed. Something else followed. In 18-month-old mice, animals carrying these grafts ran noticeably farther on a treadmill and gripped harder than sham-operated controls. Their lean mass held up better and their fat mass dropped. Bone density was slightly higher. Liver enzymes fell, senescent cells in the liver declined, and the fibrous collagen that accumulates in aging liver was reduced. White blood cell counts and inflammatory gene expression in distant muscle moved toward the levels seen in young animals. In a Y-maze test the grafted mice showed more interest in the novel arm, and fewer degenerating neurons appeared in their hippocampus.

The proposed explanation is endocrine. The graft is a factory. Serum FGF21 nearly doubled, BDNF rose, and the graft tissue itself showed elevated myokine gene expression alongside suppressed inflammatory genes. The authors argue, reasonably, that newly built muscle free of the accumulated damage in old fibers might secrete more effectively than the animal’s own aged tissue.

Then comes the clever extension. Because the graft is built from cultured cells, those cells can be genetically modified before implantation. The team inserted genes for parathyroid hormone and growth hormone. Mice with their parathyroid glands surgically removed, a model of a real human surgical complication, had their blood calcium and phosphate partially corrected by a graft secreting the hormone continuously. That is a different proposition from the anti-aging claim: a living, slow-release hormone depot made from a patient’s own cells.

Two things should restrain enthusiasm. The investigators state plainly that they were not blinded to which mice received grafts, and several of the headline outcomes are exactly the kind that unblinded assessment distorts: how far a mouse runs when prodded, how hard it grips, how long it lingers in a maze arm.

Insights

What the data do offer is a calibration of how large an effect contracting muscle mass can produce. In 18-month-old mice, grafts were associated with 43 percent greater running distance, with a standardized effect size around 1.1, and 16 percent higher grip strength at an effect size near 1.4. For reference, researchers call 0.8 a large effect. Lean mass rose about 5 percent and fat mass fell about 13 percent. These are the magnitudes achievable from adding a small amount of continuously active muscle, and they are in the same range as exercise training studies in aged rodents. The implication, which is actionable, is that the mechanism being exploited here is the same one available free through resistance training and walking. The graft is a substitute for people who cannot exercise, not an upgrade for people who can.

The one biomarker worth noting is FGF21, which nearly doubled at an effect size around 2.2, the largest measured anything in the paper. FGF21 rises with fasting, exercise, and cold exposure, and is the single most plausible mediator of the systemic effects reported.

Treat the hormone-delivery result as the more near-term application. A cell-based depot secreting parathyroid hormone continuously addresses a real clinical problem, post-surgical hypoparathyroidism, better than the anti-aging framing does.

Context and Source

  • Paywalled Paper: Contractile myografts confer systemic anti-aging benefits
  • Institutions: State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing; University of Chinese Academy of Sciences; Beijing Institute for Stem Cell and Regenerative Medicine; National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, Chinese PLA General Hospital, Beijing.
  • Country: China
  • Journal: Nature Aging (Springer Nature)
  • Impact evaluation: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

mTORC1MuscleAging3_16_9-2
mTORC1MuscleAging3_16_9-22752×1536 434 KB

Researchers at UT Health San Antonio asked whether forcing the cellular growth sensor mTORC1 permanently on accelerates muscle aging, and whether rapamycin can undo it. In 27-month-old mice carrying a muscle-specific deletion of the mTORC1 brake Depdc5, inflammatory genes and TNF-alpha protein rose, and rapamycin reversed neither. The more encouraging half of the study used common marmosets, a small primate, aging normally. Between four and twelve years old these animals gained inflammatory gene expression and lost the gene program that builds protein-making machinery. Chronic oral rapamycin reversed both. It shifted macrophage and cytokine genes two and a half to four times further than aging had shifted them, restored most of the lost translation program, and changed about three times as many genes as aging itself.

For fifteen years the longevity field has had a reliable story about mTORC1. The protein complex senses nutrients, drives growth, and suppresses cellular housekeeping. Turn it down with rapamycin and mice live longer. The story has always run in one direction, though: almost every study tests what happens when you inhibit mTORC1. Remarkably few ask the reverse question. If less mTORC1 is good, is more mTORC1 actively bad, or merely the absence of a benefit?

This paper asks the reverse question in old animals, which is where it matters. The team used a genetic trick to remove DEPDC5, part of the GATOR1 complex that normally shuts mTORC1 down when amino acids run short. Without that brake, mTORC1 in muscle runs constitutively. They flipped the switch at 22 months of age, which is roughly a 65-year-old human, and looked five months later.

The answer is that more mTORC1 is actively bad, at least at the level of signaling. Knockout muscle lit up with inflammatory and immune gene programs. TNF-alpha protein roughly doubled. Genes governing blood vessel formation went down. This was not simply the muscle looking older; the comparison group was the same age, living in the same room, eating the same food. The inflammation was stacked on top of normal aging, not a substitute for it.

In this knockout mouse model the researchers expected rapamycin to wipe out that inflammation. It did not. Rapamycin reversed the vascular gene changes and about a third of the differentially expressed genes overall, but the inflammatory transcripts and the TNF-alpha protein stayed elevated. The likely explanation is mechanical: rapamycin only partially inhibits mTORC1. It shut down S6 phosphorylation but left 4E-BP1 phosphorylation untouched, which is a known limitation of rapamycin as opposed to the newer ATP-competitive mTOR inhibitors. Whatever drives the inflammation apparently runs at least partially through the branch rapamycin does not reach.

A second experiment is a more natural experiment with aged marmosets.
A second experiment supplies the counterweight, and it is the more encouraging half of the paper. The researchers examined muscle from common marmosets, a small monkey that reaches old age around twelve years. These animals are a primate species (the same as humans) and were not engineered, so the information is much more relevant to people than the previous mouse part of the study. The marmosets simply got old. Comparing twelve-year-olds against four-year-olds, aging raised inflammatory and immune gene programs in muscle while lowering the genes that build the cell’s protein-making machinery. Marmosets given rapamycin for years showed the reverse on both counts.

The supplementary data reveal the size of that reversal, and it exceeds the aging effect it opposes. Across macrophage activation genes and tumor necrosis factor cytokine genes, rapamycin shifted expression roughly two and a half to four times further than aging had shifted it, in the opposite direction. It recovered most of the protein-synthesis gene program that age had eroded, which is a curious thing for a drug that inhibits protein synthesis to accomplish. It altered about three times as many genes as aging itself, three quarters of them downward. The drug was doing a great deal inside that tissue, and most of what it did ran against the direction of aging.

Rapamycin did not stop at returning inflammatory genes to youthful levels. It pushed them below. Macrophage activation and cytokine production in treated old marmosets sat lower than in young animals. Whether running an aged immune system quieter than a young one amounts to protection or to exposure is a question this work raises and cannot settle.

Actionable Insights

The marmoset arm is the half of this study with real translational weight, and it points in a favorable direction. Unlike the mouse experiment, which forced mTORC1 on genetically, the marmosets simply got old the ordinary way. Comparing 12.1-year-old animals against 4.2-year-old animals, six per group with sexes balanced, aging raised inflammatory and immune gene programs and lowered protein translation gene sets. Chronic oral rapamycin reversed both. That is the pattern a person taking rapamycin would actually hope for: not the suppression of an artificial lesion, but the partial normalization of a primate’s own aging muscle transcriptome.

The dose is interesting to note. Marmosets received roughly 1 mg/kg daily, five days a week. Body-surface-area normalization gives a human equivalent near 0.19 mg/kg, about 13 mg daily for a 70 kg adult, or roughly 65 mg weekly. That is approximately ten times the 5 to 7 mg weekly most longevity protocols use, and not something doctors recommend due to risks of immune suppression.

The marmoset arm is the translationally meaningful half of this study, and the supplementary figure lets it be quantified rather than described. These were primates aging normally, 12.1 years against 4.2 years, six per group with sexes balanced, not a genetic model.

Reconstructing the z-scores from the heatmaps gives the following:

Gene set Young Old Old + Rapa Effect of age Effect of rapamycin
Cytoplasmic translation +0.17 -0.26 +0.09 -0.43 +0.35
Macrophage activation +0.07 +0.18 -0.25 +0.11 -0.43
TNF superfamily cytokine production +0.03 +0.20 -0.23 +0.17 -0.42

Three magnitudes matter here. First, rapamycin moved all three gene sets by almost exactly the same amount, about 0.42 z units, and that is 2.5 to 3.8 times larger than what aging itself had done to the inflammatory sets. The drug did not merely hold the line against aging, it moved the tissue considerably further than aging had moved it.

Second, it restored 82 percent of the age-related loss in cytoplasmic translation gene expression. Aging cost 0.43 z units and rapamycin returned 0.35 of them. That a translation inhibitor restores the youthful translational gene program is counterintuitive and worth noting.

Context and Source

  • Open Access Paper: Constitutive Activation of Skeletal Muscle mTORC1 Drives Pro-Inflammatory Gene Expression in Skeletal Muscle of Aged Mice, 2026 Nov 6.
  • Institution: Department of Cellular and Integrative Physiology and the Barshop Institute for Longevity and Aging Studies, Long School of Medicine, University of Texas Health Science Center at San Antonio, with the Geriatric Research Education and Clinical Center, South Texas Veterans Healthcare System.
  • Country: United States
  • Journal: Aging Cell (Wiley, on behalf of the Anatomical Society)
  • Impact evaluation: The impact score of this journal is 7.1 (Journal Impact Factor, Clarivate), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

SixMinuteScreenForFrailtyFuture-2
SixMinuteScreenForFrailtyFuture-22752×1536 481 KB

Population aging has increased the prevalence of late-life disability, yet early risk detection remains difficult. This longitudinal cohort study followed 4,593 adults from the Whitehall II study over an eleven-year median period to determine which early old-age fitness metrics best predict future disability and mortality. Researchers evaluated ten functional measures and applied LASSO regression to isolate the most powerful predictive variables. Simple measures including waist circumference, timed chair rises, and balance assessments effectively predicted disability. These basic metrics performed competitively against complex composite metrics like the Short Physical Performance Battery. The findings strongly suggest that clinicians and longevity enthusiasts can rely on a highly accessible screening protocol to forecast long-term physical decline. Implementing this predictive tool allows for targeted early interventions to preserve physical autonomy.

As humans consistently live longer, scientific focus is shifting toward identifying actionable early warning signs of physical decline before severe disability occurs. Most existing prognostic tools rely on extensive questionnaires or composite frailty scores that are difficult to implement outside specialized geriatric centers. A recent analysis of the Whitehall II cohort reframes this diagnostic approach.

The core finding reveals that highly complex diagnostic criteria are largely unnecessary for predicting long-term independence. Researchers tracked 4,593 individuals with a mean age of 65.3 years for over a decade. They evaluated ten distinct functional tests to see which variables most accurately predicted whether a person would eventually lose the ability to perform basic daily activities.

Through machine learning analysis using LASSO regression, investigators distilled the optimal predictive model down to just a few easily accessible metrics. For predicting incident disability, defined as difficulty in at least one activity of daily living, the best model requires only a patient’s age, sex, waist circumference, walking speed, timed chair rises, and a basic balance test. To predict severe disability, defined as difficulty in at least two activities, walking speed drops out of the equation entirely.

The data highlights central adiposity as a primary driver of functional decline. Waist circumference emerged as a leading indicator of future physical limitation. When evaluated as a standalone variable, waist circumference performed as well as multifaceted frailty indices. When researchers combined this measurement with practical markers of lower extremity strength and neurological coordination, predictive accuracy improved significantly.

This research democratizes early longevity interventions. Advanced physiological laboratories are not required to assess the trajectory toward frailty. A simple tape measure and a stopwatch provide enough statistical power to predict eleven-year disability risk. The predictive set identified in this study achieved a C-statistic of 0.6617 for incident disability and 0.6955 for severe disability. This safely clears standard statistical thresholds for acceptable discrimination in population screening.

Investigators also evaluated all-cause mortality as a secondary outcome. For predicting mortality, the optimal variables included walking speed, grip strength, resting heart rate, waist circumference, balance, and a finger tapping test. However, the data showed that basic functional measures were much stronger predictors for incident disability than for lifespan extension itself. This underscores the specific utility of this tool for healthspan preservation rather than simple mortality risk assessment. Calibration tests confirmed a tight agreement between the predicted probability of functional loss and the actual observed frequencies over the eleven-year horizon.

The study signals a clear mandate for proactive care. When individuals in their early sixties assess these baseline metrics,they gain a reliable window into their physical future. Poor performance on a timed chair rise or elevated waist circumference can immediately trigger structured interventions. Progressive resistance training or metabolic rehabilitation can be initiated long before functional independence is lost. This transitions the clinical paradigm from reactive disability management to predictive functional preservation.

Actionable Insights

The primary takeaway is that basic biomechanical and metabolic self-assessments provide immense predictive power for future physical independence. You should consistently track your waist circumference, walking speed, timed chair rises, and balance.

The study quantifies the precise penalty of poor physical performance. Every one standard deviation increase in waist circumference corresponds to a 34 percent increase in the hazard risk of developing a basic disability over the next eleven years. Similarly, a one standard deviation worsening in walking speed or timed chair rises increases your hazard of disability by 15 percent.

Because central adiposity strongly forecasts severe physical impairment, protocols targeting visceral fat reduction should take priority over generalized weight loss strategies. The inclusion of timed chair rises and balance tests in the final predictive models indicates that preserving lower extremity power and neuromuscular control is essential. Implementing explosive lower-body resistance training and dedicated balance protocols will directly mitigate the specific vulnerabilities identified in this cohort. By treating these simple assessments as routine vital signs, you can continuously calibrate your lifestyle interventions to ensure an independent lifespan.

We provide full instructions on how you can evaluate yourself on all these metrics on this page.

Context/Source

RapAdmin

BHPCausesTreatments-2
BHPCausesTreatments-22752×1536 466 KB

This 2019 mini-review comes from urologists and prostate biologists in Vienna and Innsbruck. It summarizes what drives benign prostatic hyperplasia (BPH), the noncancerous growth of prostate tissue, and what it leads to clinically: an enlarged prostate and lower urinary tract symptoms. The authors focus mainly on the androgen pathway. Inside the prostate, testosterone is converted to the more potent dihydrotestosterone (DHT), which drives growth through the androgen receptor; finasteride and dutasteride block that conversion. They then survey newer contributors: the insulin-like growth factor (IGF) axis, estrogens, chronic inflammation, metabolic syndrome, obesity and genetics, and they briefly cover treatment. Several candidate interventions, including metformin, pomegranate extract and ginseng, have support only from rodent or cell studies.

By age 80, most men have benign prostatic hyperplasia, a slow, noncancerous overgrowth of the inner prostate. Many never notice it. Others get a weak stream, urgency and repeated trips to the bathroom at night. Even though BPH is so common, nobody can yet explain why one man ends up with a 40-gram prostate and another with a 200-gram one.

The authors start with the oldest and firmest piece of the puzzle: hormones. The testes make testosterone, and inside the prostate an enzyme called 5-alpha reductase converts it into dihydrotestosterone, or DHT, a far more potent androgen. Men castrated before puberty, and men born without a working form of the enzyme, do not develop enlarged prostates. This is why finasteride and dutasteride, which block the enzyme, shrink the gland by 20 to 30% and lower the chances of urinary retention and surgery. Androgens appear to be necessary but not sufficient, though. Testosterone falls with age while BPH rises, so something else must tip the balance.

The review points to three candidates. The first is a growth-factor network built around IGF. IGF is raised in BPH tissue and interacts with TGF-beta, a scar-promoting signal, in the prostate’s supporting tissue. The second is chronic inflammation, which is common in BPH specimens and has been linked to faster progression and a higher risk of urinary retention. The third is metabolism. In a Baltimore cohort, each extra point of body mass index went with about 0.4 milliliters of extra prostate volume, and severely obese men had roughly 3.5 times the odds of an enlarged gland compared with men of normal weight. The authors propose that insulin resistance, a hormonal shift toward estrogen, narrowed pelvic arteries and low-grade inflammation all feed prostate growth and urinary symptoms.

Genes matter too. Twin studies put the heritability of BPH and urinary symptoms at 50 to 70%, although only one genetic variant, in the vitamin D receptor gene, has held up consistently across populations.

The review also lists some intriguing leads. The diabetes drug metformin blunted testosterone-driven prostate growth in rats, and pomegranate extract, ginseng and vanillic acid had effects in animal models. None has been tested in a proper human trial.

One clinical point is easy to miss. Among older men with urinary symptoms, about 60% have an overactive bladder, while only 30 to 40% have a prostate that is actually obstructing urine flow. Prostate size alone is a poor guide to what is causing the symptoms.

The paper has clear limits. It is a narrative overview of 26 references, not a systematic analysis. The take-home is modest but useful. Androgens set the stage for prostate growth, and metabolic health and inflammation may decide how far it goes. No long-term trial has yet shown that improving those factors actually prevents BPH.

Actionable Insights

These points combine what the review says with well-established trial data. The review itself tested nothing.

  1. Keep weight and waist in check. Each BMI point was linked to about 0.4 mL more prostate volume, which is small on its own. Severe obesity, though, carried about 3.5 times the odds of an enlarged prostate (Cohen’s d about 0.7, a medium effect). Whether losing weight shrinks the prostate has not been tested.
  2. Stay active. Separate meta-analysis data, not covered in this review, link higher physical activity to up to 25% lower BPH risk.
  3. Find out what is causing your symptoms. Bladder overactivity is present in about 60% of older men with symptoms and obstruction in only 30 to 40%, so treatment should follow testing, not prostate size alone.
  4. Match the drug to the goal. Alpha-blockers ease symptoms quickly but do not shrink the gland. 5-alpha reductase inhibitors shrink it by 20 to 30%. In a four-year trial they cut acute urinary retention from about 7% to 3% and surgery from about 10% to 5%, so roughly 1 in 20 to 25 men treated avoids one of these events. Daily tadalafil gives a modest symptom benefit.
  5. Skip the unproven options. The evidence for metformin, pomegranate and ginseng in BPH is animal-only.

Context and Source

  • Open Access Paper: Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review
  • Institutions: Department of Urology, Kaiser Franz Josef Hospital, Vienna; Sigmund Freud Private University, Vienna; Department of Urology, Medical University of Innsbruck
  • Country: Austria
  • Journal: Gerontology (S. Karger AG), 2019
  • Impact evaluation: The impact score of this journal is 3.1, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a Medium impact journal.

RapAdmin

FishConsumptionCardioRisk-2
FishConsumptionCardioRisk-22752×1536 478 KB

A systematic review and dose-response meta-analysis pooled prospective cohort studies from Japan, one of the highest fish-consuming countries, to test whether the survival benefits linked to fish in Western populations hold when even the lowest eaters consume fish regularly. Of 16 eligible studies, nine entered the meta-analysis. Comparing the highest with the lowest intake groups, higher fish consumption was associated with a 6% lower risk of death from any cause and a 15% lower risk of cardiovascular death, with almost no disagreement between studies. A spline model suggested risk fell up to about 100 grams per day and then flattened, although formal dose-response tests were not statistically significant.

Japan is one of the few places on Earth where almost nobody avoids fish. That makes it an unusually good test bed for a question nutrition researchers have argued about for decades: do the survival benefits linked to fish in Western studies keep growing as intake climbs, or do they run out?

A team from Tohoku University, Kobe University, Japan’s National Institutes of Biomedical Innovation, Health and Nutrition, and the research institute of seafood company Nissui gathered every prospective cohort study of Japanese adults that tracked fish intake and later deaths. After reviewing 113 full-text articles, they found 16 relevant studies and pooled nine.

The headline result is consistent but modest. People in the highest fish-intake groups were about 6% less likely to die from any cause during follow-up than those in the lowest groups. For cardiovascular death, the gap was larger, about 15%. Unusually for nutrition research, the individual studies barely disagreed with each other, and removing any single study did not change the picture.

The twist is what “low intake” means in Japan. In American and European cohorts, the comparison group often eats almost no fish. In Japan, the bottom group in most studies still ate roughly 18 to 46 grams a day, a couple of servings a week or more. So this analysis asks a sharper question: if you already eat fish, does eating more still help? The answer appears to be a qualified yes.

The authors also tried to map the shape of the benefit. A flexible curve fitted to four studies suggested death risk kept falling until about 100 grams a day, around one and a half typical Japanese servings, and then leveled off. Earlier global analyses had placed that plateau nearer 60 grams. However, the formal tests for a dose-response trend were not significant, and the plateau was identified by eye. It is a hypothesis, not a finding.

There are reasons for caution beyond the usual “correlation is not causation.” Two studies carry about three-quarters of the statistical weight in each main analysis. For cardiovascular death, the dominant study comes from a cohort that began in the mid-1960s, received the lowest quality score in the set, and, like the second-largest contributor, measured stroke deaths rather than all cardiovascular deaths. The heart-attack evidence is thin. Fish intake was asked about once, at the start, by questionnaire, and people who eat more fish may differ in income, activity and overall diet in ways adjustment cannot fully capture. The authors themselves rate the certainty of the evidence as low.

The study was funded by Nissui, and two of the six authors work there. That does not invalidate the analysis, which was preregistered and follows standard methods, but readers should weigh it.

What emerges is reassuring rather than revolutionary. Fish appears to remain a sensible part of a long-lived diet even at intakes far above Western norms, with the clearest signal for stroke and cardiovascular death and diminishing returns somewhere near a daily serving. Whether the effect comes from omega-3 fats, protein, vitamin D, taurine, or simply eating less of something else remains open.

Actionable Insights

These are associations, not proven effects, so treat them as reasonable bets rather than guarantees.

  1. If you eat little or no fish, moving toward regular intake is the change best supported by this and earlier data. The Japanese results suggest benefit continues up to roughly 100 grams a day (about 700 grams, or six 4-ounce servings, a week), with little extra beyond that.
  2. Expect a small individual effect. Moving from the lowest to the highest intake group was linked to about 6% lower relative risk of death from any cause. Applied to the death rate in these cohorts (about 12.6% over 4 to 19 years), that is roughly 0.5 to 0.7 fewer deaths per 100 people, so about 140 to 210 people would need to make the change to avoid one death. In standardized terms that is a Cohen’s d of about 0.03, far below the 0.2 conventionally called “small.”
  3. The cardiovascular signal is stronger: 15% lower relative risk, about 0.5 fewer cardiovascular deaths per 100 people, around 200 people per death avoided (d about 0.09). Most of this evidence concerns stroke.
  4. Whole fish is not the same as capsules. Fish-oil supplement trials are mixed, so these data do not justify pills as a substitute.
  5. At intakes near 100 grams a day, favor low-mercury species such as sardines, salmon, Atlantic or Pacific mackerel and small whole fish. Contaminants were not assessed.

Context and Source

  • Open Access Paper: Fish intake and mortality in Japan, a high fish-consuming country: a systematic review and dose-response meta-analysis of cohort studies, Published: 23 October 2026.
  • Institutions: Food and Health Science Research Institute, Nissui Corporation (Tokyo); Tohoku University Graduate School of Medicine and Graduate School of Biomedical Engineering (Miyagi); Yokohama University of Pharmacy (Kanagawa); National Institutes of Biomedical Innovation, Health and Nutrition (Osaka, corresponding author Haruki Momma); Kobe University (Hyogo)
  • Country: Japan
  • Journal: European Journal of Clinical Nutrition (Springer Nature)
  • Funding and conflicts: Funded by Nissui Corporation, a major Japanese seafood company; the two lead-listed contributors from Nissui (Yokoi, Kato) are employees.
  • Impact evaluation: The impact score of this journal is 3.2, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a Medium impact journal.

RapAdmin

CreatineMuscle10G-2
CreatineMuscle10G-21920×1072 605 KB

A 12-week randomized, double-blind trial from Texas A&M University tested 10 grams per day of creatine monohydrate in 64 sedentary adults aged 45 to 65. Participants first chose whether to join a supervised resistance and aerobic training program with a modest calorie deficit or to keep their normal routine, and were then randomly assigned to creatine or a maltodextrin placebo. Creatine increased DXA-measured lean mass by roughly 1.1 to 1.3 kg relative to placebo in both settings, improved leg and bench press strength, and produced a larger drop in body fat percentage when combined with exercise and dieting. The authors also report gains on some memory tests, lower HbA1c and better lipid profiles.

Most people who diet in middle age lose more than fat. A meaningful share of the weight that comes off is muscle, the tissue that keeps us strong, mobile and metabolically healthy as we age. A new trial from Richard Kreider’s Exercise and Sport Nutrition Lab at Texas A&M asks whether one of the cheapest and best-studied supplements available, creatine monohydrate, can shift that trade in our favor.

The team recruited 73 healthy but sedentary adults aged 45 to 65, most of them overweight. Each volunteer chose whether to join a supervised program of resistance and aerobic training three times a week, paired with a diet cut by 300 to 500 calories a day, or to carry on as usual. Within each group, participants were randomly assigned to 5 grams of creatine twice daily or an identical-looking carbohydrate powder for 12 weeks. Sixty-four finished.

The muscle results are the strongest part of the paper. In the exercise and diet group, creatine users ended with about 1.1 kg more lean mass than placebo users, whose lean mass barely moved. Creatine users who did no training gained a similar amount relative to their own placebo group. Leg press strength rose by roughly a third in the exercising creatine group, about double the gain from exercise alone, and bench press followed a similar pattern. Body fat percentage fell further when creatine was added.

There is an important asterisk. Creatine draws water into muscle cells, and DXA scanners count that water as lean tissue. Lean mass in the exercising creatine group peaked at six weeks and then slipped back, a pattern that fits early water loading at least as well as new muscle protein. The extra drop in body fat percentage partly reflects a larger denominator, since actual fat mass losses looked similar with or without creatine.

The brain findings warrant more caution. The researchers used a relatively high dose because only a small fraction of oral creatine reaches the brain, and they ran a large battery of memory, attention and reaction-time tests. Across eight cognitive tasks, none showed a significant overall difference between groups over time. The positive claims rest on individual comparisons, such as a temporary improvement in delayed word recall at six weeks, alongside results pointing the other way, including more attention errors and higher tension scores in some creatine groups. The authors themselves call these findings exploratory.

Blood work hinted that creatine without exercise lowered HbA1c, a marker of average blood sugar, by roughly a quarter of a percentage point versus placebo, with no change in fasting glucose. In people with normal glucose, that is a lead worth following, not a reason to treat creatine as a glucose-lowering therapy.

Context matters. The corresponding author chairs the scientific advisory board of AlzChem, which manufactured and donated the creatine, and he is also one of the journal’s editors-in-chief. That does not invalidate the data, but it raises the bar for independent replication.

The take-home is modest but useful: creatine appears to help middle-aged adults keep or build muscle and strength, including while dieting. Claims that it sharpens the healthy midlife brain remain unproven.

Actionable Insights

  • Muscle: 10 g/day (two 5 g doses) added about 1.1 to 1.3 kg of lean mass over 12 weeks versus placebo. That is roughly 2% of a typical participant’s lean mass, and some of it is water stored in muscle. The effect size is moderate to large (estimated Cohen’s d about 0.7 to 0.8).
  • Strength: Leg press 1RM rose about 33% with creatine plus training versus about 17% with training alone. A gap of that size is likely to matter for everyday function.
  • Dieting: Creatine appears to protect lean tissue during a calorie deficit. Expect the scale to read 1 to 2 kg higher than it otherwise would early on. That is water, not fat.
  • Memory: Do not take creatine expecting cognitive gains if you are healthy and well rested. No cognitive domain showed a reliable effect here.
  • Kidney labs: Serum creatinine rose (under 0.15 mg/dL) and calculated eGFR fell by up to 20% in exercising creatine users. This is a known measurement artifact, not kidney injury, but tell your physician and consider cystatin C for a cleaner reading.
  • Protein: Participants averaged only 0.94 g/kg/day, well below the 1.2 g/kg/day or more commonly advised for older adults who train.
  • Dose: 3 to 5 g/day is the established muscle dose. This trial did not test whether 10 g outperforms it.

Context and Source

RapAdmin

HeartRateHRVAging-2
HeartRateHRVAging-21920×1072 609 KB

This single-author narrative review argues that resting heart rate and heart rate variability should be treated not merely as clinical vital signs but as accessible biomarkers of biological aging. It assembles three evidence streams: comparative biology showing that across mammals heart rate scales inversely with body mass and lifespan; large epidemiological cohorts, including a combined Taiwanese and Norwegian analysis of 692,217 adults, showing that elevated resting heart rate predicts cardiovascular and all-cause mortality; and clinical studies showing that reduced heart rate variability predicts adverse outcomes after myocardial infarction, in heart failure, and in diabetes. The proposed mechanisms are sympathetic overactivation, parasympathetic withdrawal, neuroendocrine stress activation, oxidative stress, inflammation, baroreflex failure, and structural remodeling. The review proposes wearables and machine learning as the route to individualized longitudinal tracking.

The pulse is the oldest diagnostic instrument in medicine and, on the evidence assembled here, one of the more underrated ones. This review makes the case that two numbers anyone with a cheap wrist device can read, resting heart rate and heart rate variability, carry real information about how fast a person is aging.

The comparative biology opening is the most quotable and the least useful. A shrew’s heart runs near a thousand beats a minute and the animal is dead within a couple of years. An elephant idles around forty and lives for decades. Across mammals, heart rate scales roughly as body mass to the minus one-quarter power, and the total number of heartbeats in a lifetime converges on something near a billion across many species. The review presents the old fixed-heartbeat hypothesis, then correctly labels it oversimplified, while still letting it set the tone.

The human epidemiology carries the argument. Across Framingham, the Chicago studies, NHANES, French and Finnish and Swedish and Chinese and Japanese and Korean cohorts, higher resting heart rate predicts cardiovascular and all-cause death after adjustment for the obvious confounders. The largest analysis, pooling the Taiwan MJ and Norwegian HUNT cohorts across 692,217 adults over 25 years, found that a resting pulse in the eighties and nineties cost measurable life expectancy, with the risk at 90 to 99 beats per minute comparable to carrying hypertension. That comparison is the single most striking line in the paper.

Heart rate variability (HRV) tells a different story. Where resting heart rate reports how hard the autonomic system is leaning on the heart, variability reports how flexibly it can respond. In Framingham, a one standard deviation drop in a standard variability index was associated with roughly a 47 percent higher hazard of new cardiac events. In heart failure patients, the gradient is brutal: mortality ran 5.5 percent in those with the highest variability and 51.4 percent in those with the lowest.

The review also flags that the relationship is not monotonic. A Korean cohort of 31,697 adults found higher cardiovascular mortality both above 80 beats per minute and below 60. The Rotterdam Study found that unusually high variability also predicted cardiac death in older adults.

Actionable Insights

A hazard ratio is how much a person’s risk of an event multiplies relative to a comparison group. A hazard ratio of 1.5 means 50 percent higher risk. These are observational associations, not proof that changing the number changes the outcome.

Resting heart rate. Pulling the per-unit figures from the cohorts tabulated here: a Swedish cohort found about 3 percent higher all-cause mortality per additional beat per minute. FINRISK found 24 percent higher cardiovascular death in men and 32 percent in women per 15 beats. Working those back, roughly 15 to 25 percent lower mortality risk per 10 beats lower is a defensible central estimate, with one French cohort reporting a near doubling per 15 beats at the extreme end. In practical terms, 80 beats per minute is where the risk curve clearly steepens across multiple independent cohorts.

Heart rate variability. In Framingham, a one standard deviation drop in SDNN carried a hazard ratio of 1.47 for incident cardiac events and 1.38 for mortality in older adults. In heart failure, SDNN below 50 milliseconds marked a group with roughly nine times the mortality of those above 100.

Two cautions that matter. Lower is not uniformly better: one Korean cohort found elevated cardiovascular mortality below 60 beats per minute as well as above 80. And resting heart rate is heavily shaped by cardiorespiratory fitness, so these associations are partly measuring something else.

Context and Source

Leitura Relacionada: